OBJECTIVE: A preliminary study to examine the efficacy of osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) symptoms and parenting behaviors in mothers with ADHD who had children with ADHD. METHOD:Participants included 23 mother-child dyads in which both were diagnosed with DSM-IV ADHD. Mothers underwent a 5-week, double-blind titration (placebo, 36 mg/day, 54 mg/day, 72 mg/day, 90 mg/day) to an optimal dose of OROS methylphenidate, followed by random assignment to 2 weeks of placebo or their maximally effective dose. Primary outcome measures included maternal ADHD symptoms (Conners' Adult ADHD Rating Scale) and parenting (Alabama Parenting Questionnaire). Secondary outcomes included side effects ratings. Data were collected from December 2004 until August 2006. RESULTS: During Phase 1, mothers reported significant decreases in inattention (p < .001) and hyperactivity/impulsivity (p < .01) with increases in OROS methylphenidate dose. As dose increased, significant reductions in inconsistent discipline (p < .01) and corporal punishment use (p < .005) were also demonstrated. During Phase 2, small effects on inattention (d = 0.46) and hyperactivity/impulsivity (d = 0.38) were found for those randomly assigned to medication versus placebo. In addition, medium to large medication effects were found on maternal involvement (d = 0.52), poor monitoring/supervision (d = 0.70), and inconsistent discipline (d = 0.71), with small effects on corporal punishment (d = 0.42). During both phases, few adverse effects were noted. CONCLUSIONS:OROS methylphenidate was well tolerated and was associated with significant improvement in maternal ADHD symptoms and parenting. Variable effects on parenting suggest that behavioral interventions may be necessary to address impairments in parenting among adults with ADHD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00318981. Copyright 2008 Physicians Postgraduate Press, Inc.
RCT Entities:
OBJECTIVE: A preliminary study to examine the efficacy of osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) symptoms and parenting behaviors in mothers with ADHD who had children with ADHD. METHOD:Participants included 23 mother-child dyads in which both were diagnosed with DSM-IV ADHD. Mothers underwent a 5-week, double-blind titration (placebo, 36 mg/day, 54 mg/day, 72 mg/day, 90 mg/day) to an optimal dose of OROS methylphenidate, followed by random assignment to 2 weeks of placebo or their maximally effective dose. Primary outcome measures included maternal ADHD symptoms (Conners' Adult ADHD Rating Scale) and parenting (Alabama Parenting Questionnaire). Secondary outcomes included side effects ratings. Data were collected from December 2004 until August 2006. RESULTS: During Phase 1, mothers reported significant decreases in inattention (p < .001) and hyperactivity/impulsivity (p < .01) with increases in OROS methylphenidate dose. As dose increased, significant reductions in inconsistent discipline (p < .01) and corporal punishment use (p < .005) were also demonstrated. During Phase 2, small effects on inattention (d = 0.46) and hyperactivity/impulsivity (d = 0.38) were found for those randomly assigned to medication versus placebo. In addition, medium to large medication effects were found on maternal involvement (d = 0.52), poor monitoring/supervision (d = 0.70), and inconsistent discipline (d = 0.71), with small effects on corporal punishment (d = 0.42). During both phases, few adverse effects were noted. CONCLUSIONS:OROS methylphenidate was well tolerated and was associated with significant improvement in maternal ADHD symptoms and parenting. Variable effects on parenting suggest that behavioral interventions may be necessary to address impairments in parenting among adults with ADHD. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00318981. Copyright 2008 Physicians Postgraduate Press, Inc.
Authors: Alexander Häge; Barbara Alm; Tobias Banaschewski; Katja Becker; Michael Colla; Christine Freitag; Julia Geissler; Alexander von Gontard; Erika Graf; Barbara Haack-Dees; Susann Hänig; Klaus Hennighausen; Sarah Hohmann; Christian Jacob; Charlotte Jaite; Christine Jennen-Steinmetz; Viola Kappel; Swantje Matthies; Alexandra Philipsen; Luise Poustka; Wolfgang Retz; Michael Rösler; Katja Schneider-Momm; Esther Sobanski; Timo D Vloet; Andreas Warnke; Thomas Jans Journal: Eur Child Adolesc Psychiatry Date: 2018-01-23 Impact factor: 4.785
Authors: Dara E Babinski; William E Pelham; Brooke S G Molina; Elizabeth M Gnagy; Daniel A Waschbusch; Brian T Wymbs; Margaret H Sibley; Karen J Derefinko; Aparajita B Kuriyan Journal: J Atten Disord Date: 2012-11-15 Impact factor: 3.256
Authors: James G Waxmonsky; D A Waschbusch; D E Babinski; H H Humphrey; A Alfonso; K I Crum; M Bernstein; J Slavec; J N Augustus; W E Pelham Journal: CNS Drugs Date: 2014-07 Impact factor: 5.749
Authors: Dara E Babinski; James G Waxmonsky; Daniel A Waschbusch; Hugh Humphrey; Alexandra Alfonso; Kathleen I Crum; Melissa Bernstein; Janine Slavec; Junea N Augustus; William E Pelham Journal: J Child Adolesc Psychopharmacol Date: 2014-12 Impact factor: 2.576
Authors: Julia M Geissler; Timo D Vloet; Nora Strom; Charlotte Jaite; Erika Graf; Viola Kappel; Andreas Warnke; Christian Jacob; Klaus Hennighausen; Barbara Haack-Dees; Katja Schneider-Momm; Swantje Matthies; Michael Rösler; Wolfgang Retz; Susann Hänig; Alexander von Gontard; Esther Sobanski; Barbara Alm; Sarah Hohmann; Luise Poustka; Michael Colla; Laura Gentschow; Christine M Freitag; Alexander Häge; Martin Holtmann; Katja Becker; Alexandra Philipsen; Thomas Jans Journal: Eur Child Adolesc Psychiatry Date: 2019-12-05 Impact factor: 4.785